PSUSA/00001416/202405
Submitted by Anonymous (not verified) on 23 January 2025 - 10:48
PSUSA/00001416/202405
CHMP work plan 2025
Submitted by Anonymous (not verified) on 23 January 2025 - 10:39
CHMP work plan 2025
Procedural advice for orphan medicinal product designation: Guidance for sponsors
Submitted by Anonymous (not verified) on 23 January 2025 - 9:48
Procedural advice for orphan medicinal product designation: Guidance for sponsors
European Medicines Agency’s data protection notice for meeting registration forms via EUSurvey
Submitted by Anonymous (not verified) on 23 January 2025 - 7:52
European Medicines Agency’s data protection notice for meeting registration forms via EUSurvey
Parallel scientific advice processes and special product types
Submitted by Anonymous (not verified) on 22 January 2025 - 16:41
Parallel scientific advice processes and special product types
PSUSA/00001215/202406
Submitted by Anonymous (not verified) on 22 January 2025 - 16:00
PSUSA/00001215/202406
PSUSA/00000463/202404
Submitted by Anonymous (not verified) on 22 January 2025 - 15:59
PSUSA/00000463/202404
PSUSA/00001913/202405
Submitted by Anonymous (not verified) on 22 January 2025 - 15:58
PSUSA/00001913/202405
PSUSA/00010693/202404
Submitted by Anonymous (not verified) on 22 January 2025 - 15:56
PSUSA/00010693/202404
Human medicines European public assessment report (EPAR): Renagel, sevelamer, Date of authorisation: 28/01/2000, Revision: 38, Status: Authorised
Submitted by Anonymous (not verified) on 22 January 2025 - 15:36
Human medicines European public assessment report (EPAR): Renagel, sevelamer, Date of authorisation: 28/01/2000, Revision: 38, Status: Authorised